Filtered By:
Cancer: Breast Cancer
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 677 results found since Jan 2013.
A review on the role of ZEB1-AS1 in human disorders
Pathol Res Pract. 2023 Apr 26;245:154486. doi: 10.1016/j.prp.2023.154486. Online ahead of print.ABSTRACTZEB1 Antisense RNA 1 (ZEB1-AS1) is a type of RNA characterized as long non-coding RNA (lncRNA). This lncRNA has important regulatory roles on its related gene, Zinc Finger E-Box Binding Homeobox 1 (ZEB1). In addition, role of ZEB1-AS1 has been approved in diverse malignancies such as colorectal cancer, breast cancer, glioma, hepatocellular carcinoma and gastric cancer. ZEB1-AS1 serves as a sponge for a number of microRNAs, namely miR-577, miR-335-5p, miR-101, miR-505-3p, miR-455-3p, miR-205, miR-23a, miR-365a-3p, miR-302...
Source: Pathology, Research and Practice - April 30, 2023 Category: Pathology Authors: Soudeh Ghafouri-Fard Arian Askari Kimia Behzad Moghadam Bashdar Mahmud Hussen Mohammad Taheri Mohammad Samadian Source Type: research
Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
ConclusionFor patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.
Source: Clinical and Translational Oncology - April 23, 2023 Category: Cancer & Oncology Source Type: research
Unknown Causes of Death in Cancer Patients
CONCLUSION: Of the patients, 7.4% died of unknown causes during follow-up and the proportion of death was higher with longer follow-up and among more indolent cancers. The attribution of high percentages of unknown COD to cancer or non-cancer causes could impact population-based cancer registry studies or clinical trial outcomes with respect to measures involving CSS and mortality.PMID:37038261 | DOI:10.1097/COC.0000000000001003
Source: Clinical Breast Cancer - April 11, 2023 Category: Cancer & Oncology Authors: Siven Chinniah Mckenzee Chiam Kyle Mani Menglu Liang Daniel M Trifiletti Daniel E Spratt Vinayak K Prasad Ming Wang Leila T Tchelebi Nicholas G Zaorsky Source Type: research
Home-Based Buddhist Walking Meditation Mitigates Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients: A Randomized Controlled Trial
Conclusions: Buddhist walking meditation exercise was effective in mitigating cardiotoxicity of anthracycline chemotherapy on vascular function, aerobic fitness, and quality of life in breast cancer patients. Clinical trial registration number: NCT02676531.PMID:37036793 | DOI:10.1089/jicm.2022.0778
Source: Cancer Control - April 10, 2023 Category: Cancer & Oncology Authors: Saowalak Siripanya Napa Parinyanitikul Hirofumi Tanaka Daroonwan Suksom Source Type: research
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Cancers, Vol. 15, Pages 2077: Presence of Multi-Morbidities and Colorectal Cancer Screening Utilization among Breast Cancer Survivors
Conclusion: Among breast cancer survivors, multi-morbidities were positively associated with CRC screening.
Source: Cancers - March 30, 2023 Category: Cancer & Oncology Authors: Meng-Han Tsai Caitlyn Grunert Jacqueline B. Vo Justin X. Moore Avirup Guha Tags: Article Source Type: research
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Net benefit of diagnostic tests for multistate diseases: an indicator variables approach
J Biopharm Stat. 2023 Jan 29:1-28. doi: 10.1080/10543406.2023.2169928. Online ahead of print.ABSTRACTA limitation of the common measures of diagnostic test performance, such as sensitivity and specificity, is that they do not consider the relative importance of false negative and false positive test results, which are likely to have different clinical consequences. Therefore, the use of classification or prediction measures alone to compare diagnostic tests or biomarkers can be inconclusive for clinicians. Comparing tests on net benefit can be more conclusive because clinical consequences of misdiagnoses are considered. Th...
Source: Atherosclerosis - January 30, 2023 Category: Cardiology Authors: Hani Samawi Ferdous Ahmed Gene Pennello Jingjing Yin Source Type: research
The Association between Exposure to Second-Hand Smoke and Disease in the Chinese Population: A Systematic Review and Meta-Analysis
CONCLUSION: The effect of SHS exposure in China was similar to that in Western countries, but its definition and characterization require further clarification. Studies on the association between SHS exposure and certain diseases with high incidence rates are insufficient.PMID:36650679 | DOI:10.3967/bes2023.003
Source: Biomedical and Environmental Sciences : BES - January 18, 2023 Category: Biomedical Science Authors: Yu Tong Wang Kui Ru Hu Jian Zhao Fei Ling Ai Yu Lin Shi Xue Wei Wang Wen Yi Yang Jing Xin Wang Li Mei Ai Xia Wan Source Type: research
